The 18 analysts offering 12-month price forecasts for Fate Therapeutics Inc have a median target of 110.50, with a high estimate of 145.00 and a low estimate of 60.00. The median estimate represents a +100.91% increase from the last price of 55.00.
The current consensus among 18 polled investment analysts is to Buy stock in Fate Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.67
Reporting Date Mar 07
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.